Calydon Capital Reduces Stake in AbbVie Inc.

Hedge fund decreases position in pharmaceutical giant by 23% in Q3

Mar. 15, 2026 at 10:37am

Got story updates? Submit your updates here. ›

Calydon Capital, a hedge fund, decreased its position in AbbVie Inc. (NYSE:ABBV) by 23.0% in the third quarter, according to the company's latest 13F filing with the Securities and Exchange Commission (SEC). Calydon Capital now owns 39,551 shares of the pharmaceutical company's stock, valued at $9,158,000.

Why it matters

AbbVie is a major pharmaceutical company with a diverse product portfolio spanning immunology, oncology, neuroscience, and other therapeutic areas. Changes in institutional ownership can provide insights into market sentiment and potential shifts in the stock's performance.

The details

According to the 13F filing, Calydon Capital sold 11,791 shares of AbbVie during the third quarter, reducing its total position to 39,551 shares. The hedge fund's holdings in AbbVie now account for approximately 1.5% of its investment portfolio, making it the 12th largest position.

  • Calydon Capital decreased its position in AbbVie in the 3rd quarter of 2026.

The players

Calydon Capital

A hedge fund that decreased its position in AbbVie Inc. by 23% in the third quarter of 2026.

AbbVie Inc.

A global, research-driven biopharmaceutical company that focuses on discovering, developing, and commercializing therapies for complex and often chronic medical conditions.

Got photos? Submit your photos here. ›

The takeaway

The reduction in Calydon Capital's position in AbbVie could signal a shift in market sentiment or portfolio rebalancing by the hedge fund, but it does not necessarily indicate any broader trends or concerns about the pharmaceutical company's performance or outlook.